Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD) Device [INP104, POD-DHE] in Patients With Migraine Headache

Next Previous
Trial Profile

Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD) Device [INP104, POD-DHE] in Patients With Migraine Headache

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms STOP-301
  • Sponsors Impel Pharmaceuticals

Most Recent Events

  • 15 Jun 2023 According to an Impel Pharmaceuticals media release, data from this study will be presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.
  • 27 Apr 2023 Results of a post-hoc analysis over 24 weeks presented at the 75th Annual Meeting of the American Academy of Neurology 2023
  • 27 Apr 2023 Results (n=354) assessing the safety in migraine patients who used a triptan within 24 hours of INP104 administration, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top